SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

New 24-month HOPE-3 extension data presented at the World Muscle Society showed slower upper-limb decline among Duchenne patients treated with deramiocel, renewing optimism ahead of the FDAs decision on the therapy. Traders see the results as supportive, though some question whether they resolve the FDAs prior statistical concerns; short-squeeze claims remain speculation.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRXs recent advance and repeated tests of technical resistance dominate discussion, with bullish traders speculating about short covering and anticipating Anktiva updates, including BCG-naive data and a bladder-cancer label expansion. Others warn the gains may fade; claims of deliberate price suppression remain unverified.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is drawing attention as traders position ahead of fiscal Q1 earnings, hoping for evidence of data-center execution or new lease and readiness updates. Bulls cite its AI infrastructure pipeline, while skeptics focus on the prolonged share-price decline, potential dilution, executive compensation and whether contracted business will translate into shareholder value.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Rising Treasury yields and Fed rate-hike concerns are weighing on the Russell 2000, with traders pointing to small caps greater debt and refinancing sensitivity as they lag large-cap tech. The discussion is mostly bearish over continued weakness and possible tests of key support, though some traders see oversold conditions or cooler inflation data as reasons to expect a rebound.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhoods product summit unveiled AI trading agents, expanded-hours and weekend stock trading, prediction-market contracts, perpetual futures, and Robinhood Social, prompting debate over whether the platform expansion can drive growth or mainly encourages riskier trading. Traders are broadly discussing the sharp price swings around the announcements, with some praising the new features and others calling the presentation underwhelming or suspecting a sell-the-news move.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, and Asset Closure. The Retail segment includes sale of electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

A sharp, volatile selloff is driving discussion, with traders pointing to Scotiabanks reduced price target while others say there is no clear company-specific news behind the decline. Bulls continue to cite Vistras AI and data-center power-demand opportunity, while skeptics focus on the weak price action despite that long-term thesis.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

A judges pause in the broader cannabis rescheduling proceeding has weighed on TRLV, as traders worry that a potential Schedule III catalyst is delayed. Many call the selloff an overreaction, arguing Trulieves medical-focused business is already covered by the earlier Schedule III action, while others remain concerned about uncertainty around broader rescheduling.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins sharp decline toward its 52-week low is being linked by traders to bearish analyst commentary warning that AXON/MAX growth could be slowing and Unity could pressure market share; securities-litigation concerns add to the overhang. Bulls counter that e-commerce adoption and other growth indicators remain strong and view the selloff as an opportunity, while bears question whether growth can sustain its prior pace.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Citis downgrade to Sell, citing valuation after Modernas sharp rally on positive Phase 3 melanoma-vaccine results, is weighing on shares. Traders are divided between concerns that the oncology optimism is overextended and bullish views that the upcoming full trial data and broader mRNA cancer platform could support further gains.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategys reported Bitcoin purchase and ongoing ATM share issuance are in focus as MSTR swings with Bitcoin. Bulls view adding BTC through share sales as supportive of the per-share thesis, while bears warn that dilution and weak price action could keep the stock under pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Crude Oil Moves Higher; US Factory Orders Rise In July

U.S. stocks rose mid-session, led by materials; factory orders beat estimates. Linkhome, Purple Biotech and GitLab surged, while Tscan and Credo fell.read more...

Purple Biotech’s Patent Win Adds Armor to a Bigger Oncology Bet

Purple Biotech (NASDAQ:PPBT) just strengthened one of the most important pieces of its oncology strategy: the intellectual-property foundation behind CAPTN-3, its modular platform for conditionally activated tri-specific antibodies designed to attack tumors while potentially limiting systemic immune toxicity.

Purple Biotech CEO Gil Efron To Step Down For Health Reasons

(RTTNews) - Purple Biotech Ltd. (PPBT), a clinical-stage pharmaceutical company, Friday announced that its Chief Executive Officer, Gil Efron will step down from his role in August, due to health...

Purple Biotech Shares Soar 92% On Breakthrough For Experimental Cancer Drug

Equity

Purple Biotech's Shrinking Losses Keep Retail Sentiment In The Green, But Other Pressures Loom

As of Dec. 31, 2024, Purple Biotech had $8.2 million in cash and short-term deposits, which it expects will be sufficient to fund operations into mid-2026.

News Movers: Yesterday’s Hottest News That Could Move the Needle Today

Your Only Digest of Market-Moving News and Rumours From High-Growth, Small Cap Stocks

Purple Biotech Stock Hits Nearly 2-Month High On Cancer Drug Trial Success: Retail Thrilled

CM24 targets CEACAM1, a multi-functional membrane glycoprotein that plays a critical role in tumor invasiveness, metastasis, and immune evasion.

Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The oncology pipeline includes CM24, NT219, and CAPTN-3. The CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. The NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.

Purple Biotech Ltd - ADR

Bearish Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Current Price	$1.49
Prev Close	$1.52
Open	$1.49
Dividend Yield	0.00%
50-Day Moving Average	$1.56
Beta	0.29
Avg. Volume	81,030.87
PE Ratio	-0.05

52-Week High	$14.10
52-Week Low	$1.16
Market Capitalization	$2.46M
EPS (Annual)	-$55.40
Price to Book	0.20
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

PPBT Fundamentals